Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Gynecol Oncol. 2011 Nov 22;124(3):589–597. doi: 10.1016/j.ygyno.2011.11.019

Figure 1. HOVTAX2, a new serous ovarian carcinoma cell line.

Figure 1

A. Images of a frozen section of the patient tissue and the derivative cell line, HOVTAX2, in live culture. B. Panel showing that the STR profile for HOVTAX2 matches the STR profile of the patient tissue it was derived from. HOVTAX2 is also shown to be p53 wild-type and Rb mutant based upon protein accumulation. C. In vivo images of the diaphragm and mesentery fat of the bowel after HOVTAX2 cells were injected i.p. into 6 week old female athymic nude mice (n=5). After 12 weeks, the mice were euthanized and tumors were identified to grow on the diaphragm and mesentery fat of the bowel. Tumor number was counted and volume measured as described in the Materials and Methods. D. Cell proliferation assay illustrating HOVTAX2 naïve cells are susceptible to 72 hr treatment of 100 nM paclitaxel while HOVTAX2 paclitaxel resistant cells had no significant response. Proliferation is graphed as percentage of control average ± S.D. *p<0.05